The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization

David T. Huang(University of Pittsburgh), Derek C. Angus(University of Pittsburgh), Graham M. Snyder(University of Pittsburgh), Oscar C. Marroquin(University of Pittsburgh), Scott Berry(Queen's University), Octavia M. Peck‐Palmer(University of Pittsburgh), Russell Meyers(University of Pittsburgh), Erin K McCreary(University of Pittsburgh Medical Center), Alexandra Weissman(University of Pittsburgh), Kevin E. Kip(UPMC Health System), Meredith Axe(University of Pittsburgh), Christopher Seymour(University of Pittsburgh), Ghady Haidar(University of Pittsburgh Medical Center), Stephen Koscumb(UPMC Health System), Tina Khadem(University of Pittsburgh Medical Center), Bryan J. McVerry(University of Pittsburgh), Tami Minnier(University of Pittsburgh Medical Center), Judith A. Shovel(University of Pittsburgh Medical Center), J Ryan Bariola(University of Pittsburgh), Debbie Albin(UPMC Health System), Alan Wells(University of Pittsburgh), Mary Kay Wisniewski(University of Pittsburgh Medical Center), Mark Schmidhofer(University of Pittsburgh), Robert D. Bart(UPMC Health System), Lindsay R. Berry(Berry & Associates (United States)), Stephanie K. Montgomery(University of Pittsburgh), Kelsey Linstrum(University of Pittsburgh), Donald M. Yealy(University of Pittsburgh), Colleen Sullivan(University of Pittsburgh), David A. Nace(University of Pittsburgh), Kevin Collins(UPMC Health System), Richard J. Wadas(University of Pittsburgh)

Trials

May 25, 2021

Cited by 25

|JAMA|2016|28.1k

|Critical Care Medicine|2013|9.7k

|Intensive Care Medicine|2013|7.3k

|Intensive Care Medicine|2017|6.8k

|Critical Care Medicine|2003|6k

Related Papers